The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 ...
Sarah Longwell on the growing voting divide between the sexes, the 2025 elections, and how Donald Trump remade electoral ...